From Hitachi Medical Corporation (HMC), sales, marketing and service in the US by Hitachi Medical Systems America Inc.;
Powerful, flexible, and fast, the HI VISION™ 8500 - EUB-8500 diagnostic ultrasound scanner combines leading edge technologies with user-oriented operation for exceptional imaging and functionality.
Available exclusively on the 8500, SonoElastography provides a new perspective on the physical properties of tumors and masses by determining and displaying the relative stiffness of tissue.

From Hitachi Medical Corporation (HMC);
The HI VISION™ 6500 - EUB-6500 high resolution digital ultrasound system offers advanced clinical imaging, enhanced operating efficiency, and remarkable clinical flexibility, all in robust and versatile configuration that simply represents a better clinical solution in a variety of real-world, real-work arenas.

In June 2007 Tyco International Ltd. completed the separation of its healthcare business, which is named Covidien. Mallinckrodt, Inc. is now part of Covidien Ltd. The company makes and distributes products for respiratory care; bulk and dosage pharmaceuticals, primarily for pain relief and addiction therapy; and imaging agents for magnetic resonance, ultrasound, x-ray, and nuclear medicine applications. With worldwide manufacturing and distribution facilities and sales offices, Mallinckrodt, Inc. sells its products worldwide.
Albunex was one of the first marketed ultrasound contrast agents. Currently, Mallinckrodt discontinued the manufacturing and development of ultrasound contrast agents.

Ultrasound Contrast Agents:

The Germany-based pharmaceutical company is the result of the take-over of Schering AG by Bayer AG in 2006. The Bayer Schering Pharma AG is part of the Bayer HealthCare AG, which represents the pharmaceutical part of the Bayer Group.
The company makes ultrasound, x-ray and MRI contrast media, drugs for treating cancer, multiple-sclerosis, heart and nervous system disorders and severe skin conditions.
In general, its activities are focused on four business areas: Fertility control & hormone therapy, diagnostics & radiopharmaceuticals, dermatology as well as specialized therapeutics for disabling diseases in the fields of the central nervous system, oncology and cardiovascular system.
Currently, Bayer Schering Pharma discontinued the manufacturing and development of ultrasound contrast agents.

Ultrasound Contrast Agents: